ViroGates A/S
CSE:VIRO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
ViroGates A/S
Income from Continuing Operations
ViroGates A/S
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
V
|
ViroGates A/S
CSE:VIRO
|
Income from Continuing Operations
-kr12.4m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
GN Store Nord A/S
CSE:GN
|
Income from Continuing Operations
kr710m
|
CAGR 3-Years
8%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-1%
|
|
|
Ambu A/S
CSE:AMBU B
|
Income from Continuing Operations
kr544m
|
CAGR 3-Years
79%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Demant A/S
CSE:DEMANT
|
Income from Continuing Operations
kr2.4B
|
CAGR 3-Years
1%
|
CAGR 5-Years
16%
|
CAGR 10-Years
5%
|
|
ViroGates A/S
Glance View
ViroGates A/S develops and markets prognostic products for the healthcare sector. Its develops a product line suPARnostic, which measures the amount of amount of soluble urokinase Plasminogen Activator Receptor protein (suPAR) in human blood. The plasma level of suPAR reflects immune activation and is increased in such infectious diseases as HIV-1-infection, malaria, tuberculosis, Streptococcus pneumonia bacteraemia, sepsis, pneumococcal pneumonia and bacterial and viral CNS infection. Also, high suPAR levels are associated with increased inflammation, disease progression and risk of mortality. Thus, measuring suPAR levels serves as a marker to determine chances for survival upon hospital admission, as well as for monitoring for prevention of disease progression and earlier intervention time point. suPARnostic has two versions: Quantitative Point of Care Quick Triage test, which serves for patient triage in acute care, and Quantitative ELISA Assay that aims at clinical routine use.
See Also
What is ViroGates A/S's Income from Continuing Operations?
Income from Continuing Operations
-12.4m
DKK
Based on the financial report for Sep 30, 2025, ViroGates A/S's Income from Continuing Operations amounts to -12.4m DKK.
What is ViroGates A/S's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
10%
Over the last year, the Income from Continuing Operations growth was 6%. The average annual Income from Continuing Operations growth rates for ViroGates A/S have been -1% over the past three years , 10% over the past five years .
